Introduction
Osteoporosis is a silent disease until it is complicated by fractures that can occur following minimal trauma. The disease can be prevented, diagnosed and treated before any fracture occurs. Prevention, detection and treatment of www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i3.139 osteoporosis should be a mandate of primary care providers 1 . Osteoporosis is second only to cardiovascular disease as a leading health care problem, according to the World Health Organization. Worldwide, the lifetime risk for women to have an osteoporotic fracture is 30-40% 2 . Because of related morbidity, disability, diminished quality of life, and mortality, osteoporosis and fractures associated with it are major public health concern 3 . Since the National Osteoporosis Foundation NOF first published the Guide in 1999, it has become increasingly clear that many patients are not being given appropriate information about prevention; too many patients are not being prescribed any of the FDAapproved, effective therapies. This Guide offers concise recommendations regarding prevention, risk assessment, diagnosis and treatment of osteoporosis in postmenopausal women and men age 50 and older. It includes indications for bone densitometry and fracture risk thresholds for intervention with pharmacologic agents 1 . Dualenergy
x-ray Absorptiometry (DXA) measurement of the hip and spine is the technology now used to establish or confirm a diagnosis of osteoporosis, predict future fracture risk and monitor patients by performing serial assessments 4. Bone Biomarkers are released into the circulation during the process of bone formation and resorption, providing information about the dynamic process of bone metabolism. During bone remodeling, bone formation by osteoblasts and bone resorption by osteoclasts are tightly coupled in time and space within the bone multicellular unit 5 . Drugs that promote bone formation (e.g. parathyroid hormone) increase biomarkers of formation and resorption, and drugs that inhibit resorption (e.g. Bisphosphonates) decrease biomarkers of formation and resorption 6 . Biomarkers of bone turnover predict fractures and changes in bone mineral density in adults, and can be used to monitor the effectiveness of therapy 7, 8 . Numerous studies have demonstrated good correlations between biomarkers of bone metabolism and the actual rate of bone turnover, as quantified by calcium kinetics studies 9 , or by histomorphometric analyses of labeled bone biopsies 10 . Although biochemical markers of bone turnover may be a more sensitive way of monitoring bone response, their use is subject to the previously noted limitations. Nevertheless, decreases in bone resorption markers measured 3 to 6 months after initiating antiresorptive therapy or increases in formation markers 1 to 3 months after starting anabolic therapy predict the subsequent increases in BMD and reduction in fracture rates and make them an attractive consideration as part of the clinical management of pharmacologic therapy 11 . Osteocalcin (OC), a bone-specific protein synthesized by the osteoblasts in bone, is the major non-collagen protein in the bone matrix. It has a molecular weight of 5,800 Da and contains 49 amino acids, including 3 gamma carboxyl glutamic acid residues that facilitate the binding of OC to hydroxyapatite in bone 12 . The serum OC level, a sensitive marker of bone production, is associated with a high bone turnover rate and decreased BMD, and correlates well with histomorphometric indices of bone formation 13 . Bone Markers of bone turnover are considered useful diagnostic tools for the evaluation of bone formation and resorption. We measured serum OC and total serum alkaline phosphatase (ALP) activity as markers of bone formation. The objectives of this study were to compare between these bone marrow markers and Dexa Scan in diagnosis and therapeutic follow up for predicting the osteoporosis by taking into consideration age, body mass index (BMI), and menopausal status. What are Bone Biomarkers: bone biomarker "Vit D3, PTH, ALK, C-Terminal Telopeptides, Osteocalcin" for evaluation & monitoring bone formation and resorption turnover in the blood as indicators for the osteoporosis level in the body. T score -This number shows the amount of bone have compared with a young adult of the same gender with peak bone mass. A score above -1 is considered normal. A score between -1 and -2.5 is classified as osteopenia (low bone mass). A score below -2.5 is defined as osteoporosis. The T score is used to estimate the risk of developing fracture.
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Results
We We detected the Dexa scan Absorptiometry are superior & more sensitive from the index data of same 100 Osteoporotic patients in early diagnosis 100% compared to bone biomarkers in diagnostic fact which is reach to 85%. Also, we detected 33% after 24 months in post therapy treatment follow up for Dexa scan Compare to 78% in bone biomarkers to same patients, also for the same follow up period rates times, which is more sensitive index scores in osteoporotic patients. 
Discussion
Osteoporosis is a systemic disease characterized by low bone mass and microarchitectural deterioration of bone tissue, resulting in an increased risk of fracture. While the level of bone mass can be estimated by measuring bone mineral density (BMD) using dual X-ray absorptiometry (DXA), its measurement does not capture all the risk factors for fracture. Quantitative changes in skeletal turnover can be assessed easily and noninvasively by the measurement of serum and urinary biochemical markers; the most sensitive markers include serum osteocalcin, bone specific alkaline phosphatase, Vitamin D3, Parathyroid Hormone PTH assessments. MICHAEL P. J.etal, support our study, they recommend using dual energy x-ray absorptiometry to screen all women 65 years and older evidence to recommend screening for osteoporosis in patients with newly diagnosed osteoporosis, suggested laboratory tests to identify secondary causes include serum 25hydroxyvitamin D, calcium, creatinine, and thyroid-stimulating hormone 14, 15, 16, 17, 18 . After initiation of treatment, the need for follow-up bone density testing is uncertain. These confirmed our results data requirements of Bone Biomarkers as diagnostic factors during follow up treatments. these supportive ideas confirm our study results data 19, 20 .WHOWorld Health Organization. Assessment of fracture risk osteoporotic patients, Kanis J., they evaluated other methods for diagnosing osteoporosis that have been used extensively in clinical trials and epidemiological studies. These include radiological assessments and Bone Turnover Markers (BTM). These supported our study to use the Dexa Scan Absorptiometry plus Bone Biomarkers both in diagnostic & Therapeutic follow up of Osteoporotic patients with proper method of evaluation which is for diagnosis, plus which is for treatment follow up 21, 22 . Combination BMD with BTM could improve fracture prediction in postmenopausal women. One advantage of biochemical markers compared to BMD is early estimation of treatment effect. Significant changes in BTM can be seen during antiresorptive therapy after a few weeks of treatment; whereas individual monitoring with DXA usually requires 1-2 years to identify significant changes. As adherence is an important issue of long-term therapy in chronic disease, it has been suggested that BTM could be used in clinical practice to assess the patient's adherence to treatment and also provide feedback on the effectiveness of the medication 23, 24, 25, 26 . In Our study confirm the usage these two methods, theDexa Scan Absorptiometry & Bone Biomarkersduring diagnostic criteria, plus evaluation during post therapeutic treatment follow up. The Dexa Scan Absorptiometry are more sensitive index in diagnostic determination, plus Bone Biomarkers method are superior in post therapeutic treatment follow up of osteoporotic patients.
